Posted on February 8, 2010 by Sitemaster
We have commented previously on the increasing number of papers that appear to be looking with greater clarity at issues related to the adverse consequences of prostate cancer therapy. A new paper on the impact of “sexual bother” (for which you can read “physical or psychological distress related to sexual intercourse”) appears to be another paper in this “series.” … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: erectile dysfunction, radical prostatectomy, RP, sexual bother | Leave a Comment »
Posted on February 8, 2010 by Sitemaster
The potential of lycopene (a natural product found at relatively high levels in tomatoes) to prevent prostate cancer is still much debated by the scientific community. By contrast, the potential of advertising to influence consumer behavior is not! So … READ MORE …
Filed under: Prevention | Tagged: lycopene, super-food, tomato | 1 Comment »
Posted on February 7, 2010 by Sitemaster
Today’s news reports address recent articles on:
- Ethnicity and first-line treatment for localized prostate cancer
- Management of biochemical relapse after first-line radiation therapy for localized disease
- “Pelvic floor rehabilitation” therapy after nerve-sparing surgery
- The DAB2IP gene and metastatic prostate cancer … READ MORE …
Filed under: Drugs in development, Management, Prevention, Treatment, Uncategorized | Tagged: biochemical relapse, DAB2IP, ethnicity, metastasis, pelvic floor, radiation, rehabilitation, Treatment | Leave a Comment »
Posted on February 6, 2010 by Sitemaster
Maybe 20-30 percent of all prostate cancer patients will be told, today, after a radical prostatectomy, that they a have a positive surgical margin. But exactly what impact a positive surgical margin has on a patient’s risk for disease recurrence has never been very clear. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: positive, prognosis, radical prostatectomy, surgical. margin | 4 Comments »
Posted on February 5, 2010 by Sitemaster
A new report from another group of Canadian researchers has reported a twofold to fourfold increase in the rate of hospital admissions in Ontario within 30 days of the procedure for men receiving a transrectal ultrasound-guided (TRUS-guided) prostate biopsy between 1996 and 2005. … READ MORE …
Filed under: Diagnosis, Risk, Uncategorized | Tagged: biopsy, complications, infection, Ontario, TRUS-guided | 3 Comments »
Posted on February 4, 2010 by Sitemaster
According to a group of researchers at Queen’s University in Kingston, Ontario, a very low dose of nitroglycerin may be able to delay the progression of prostate cancer in men with a rising PSA after standard first-line treatment with radiotherapy or surgery. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: nitroglycerin, progressive, second-line | Leave a Comment »
Posted on February 3, 2010 by Sitemaster
In today’s (slightly belated) news reports, we comment on studies dealing with:
- A possible association between hypertension and later diagnosis of prostate cancer
- Appropriate selection of high-risk patients for RALP
- Optimization of the appropriate use of docetaxel + prednisone in treatment of CRPC … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: CRPC, docetaxel, high-risk patients, hypertension, prednisone, RALP, risk, robot-assisted laparoscopic prostatectomy | Leave a Comment »
Posted on February 3, 2010 by Sitemaster
Courtland Milloy is an African-American journalist in Washington, DC. Recently, he was diagnosed with prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Diagnosis, reaction | 1 Comment »
Posted on February 2, 2010 by Sitemaster
The American Heart Association, the American Cancer Society, and the American Urology Association have come together to issue a joint “science advisory” on androgen deprivation therapy (ADT) and cardiovascular risk. The document has also been endorsed by the American Society for Radiation Oncology. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, cardiovascular, risk, science advisory | Leave a Comment »
Posted on February 1, 2010 by Sitemaster
Today’s news reports address:
- Daily fat intake and risk for prostate cancer
- Salvage RALP as a treatment for patients in biochemical relapse after first-line EBRT
- Phase II data on fenretinide as a possible treatment for HRPC … READ MORE …
Filed under: Drugs in development, Management, Prevention, Risk, Treatment | Tagged: fat intake, fatty acids, fenretinide, MUFA, PUFA, RALP, robot-assisted laparoscopic prostatectomy, salvage, SFA | Leave a Comment »
Posted on February 1, 2010 by Sitemaster
A newly published report suggests that sexual function does indeed decline after external beam radiation therapy (EBRT) for prostate cancer — but only over the first 2 years post-treatment. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: EBRT, ED, erectile dysfucntion, external beam radiation therapy, sexual function | Leave a Comment »
Posted on January 30, 2010 by Sitemaster
This series of 16 video interviews was recorded at the annual symposium of the Prostate Cancer Research Institute in Los Angeles, California, in September 2009. It includes interviews with 9 physicians and 6 patient advocates, and is now available on the Prostate Cancer International web site as well as on YouTube.
Filed under: Uncategorized | Comments Off
Posted on January 30, 2010 by Sitemaster
A newly published study has compared the clinical and pathological characteristics of screen-detected and clinically diagnosed prostate cancers in Chinese men. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: China, detection, screening | 3 Comments »
Posted on January 29, 2010 by Sitemaster
Today’s news reports address:
- Statins and prostate cancer prevention
- 10-year results of low-dose brachytherapy in a Spanish patient cohort
- Selective nuclear androgen receptor exporters (SNAREs) … READ MORE …
Filed under: Uncategorized | Tagged: 10-year survival, prevention. brachytherapy, selective nuclear androgen receptor exporters, SNARE, statins | Leave a Comment »
Posted on January 28, 2010 by Sitemaster
Guidelines suggest that the optimal management of patients with castration-resistant prostate cancer (CRPC) — also known as hormone-refractory prostate cancer or HRPC — is participation in a randomized clinical trial. But encouraging community-based clinicians to enroll their patients in clinical trials has long been problematic. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: clinical trials, CRPC, eligibility | 1 Comment »
SUPPORT 
Search for new and
ongoing trials on the
CTAG PCa web site
